/BCDA
BCDA Stock - BioCardia, Inc.
Healthcare|BiotechnologyNASDAQ
$1.27-0.78%
$0.01 (-0.78%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.26 – $1.28
TARGET (TP)$1.46
STOP LOSS$1.17
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.66
52W High$3.20
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $58,000 | $477,000 | $1.35M | $1.01M | $145,000 |
| Gross Profit | $-4,329,000 | $-7,249,000 | $-7,482,000 | $375,000 | $141,000 |
| Gross Margin | -7463.8% | -1519.7% | -553.4% | 36.9% | 97.2% |
| Operating Income | $-8,000,999 | $-11,644,000 | $-11,901,000 | $-12,630,000 | $-15,529,000 |
| Net Income | $-7,946,000 | $-11,571,000 | $-11,907,000 | $-12,621,000 | $-15,004,000 |
| Net Margin | -13700.0% | -2425.8% | -880.7% | -1243.4% | -10347.6% |
| EPS | $-2.90 | $-8.19 | $-10.05 | $-11.19 | $-22.20 |
Company Overview
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BCDABeat Rate
53%
Last 19 quarters
Avg Surprise
-89.6%
EPS vs Estimate
Beats / Misses
10/7
2 met exactly
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
+18.2%
$-1.35vs$-1.65
Q2 24
+55.0%
$-1.35vs$-3.00
Q3 24
-780.0%
$-0.88vs$-0.10
Q4 24
+48.7%
$-0.61vs$-1.19
Q1 25
+71.3%
$-0.25vs$-0.87
Q2 25
-51.3%
$-0.59vs$-0.39
Q3 25
-60.0%
$-0.40vs$-0.25
Q4 25
+4.0%
$-0.24vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.25 | $-0.40 | -60.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.39 | $-0.59 | -51.3% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.87 | $-0.25 | +71.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-1.19 | $-0.61 | +48.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.10 | $-0.88 | -780.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-3.00 | $-1.35 | +55.0% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-1.65 | $-1.35 | +18.2% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.80 | $-1.80 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-2.25 | $-2.55 | -13.3% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-1.95 | $-2.55 | -30.8% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-2.70 | $-2.40 | +11.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-3.45 | $-2.55 | +26.1% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-4.20 | $-2.10 | +50.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-2.25 | $-2.85 | -26.7% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-3.15 | $-3.15 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-0.21 | $-2.40 | -1042.9% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-3.15 | $-3.00 | +4.8% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-3.15 | $-2.70 | +14.3% | ✓ BEAT |
Latest News
BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF
➖ NeutralBenzinga•Dec 16, 2025, 01:08 PM
BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:13 PM
BioCardia Announces First Patient Enrolled At Henry Ford Health In Ongoing Phase 3 CardiAMP HF II Clinical Trial For Patients With Ischemic Heart Failure Of Reduced Ejection Fraction
📈 PositiveBenzinga•Nov 10, 2025, 01:31 PM•Also:
BioCardia shares are trading higher. The company recently announced University of Wisconsin enrolled first patient in phase 3 CardiAMP HF II cell therapy pivotal trial.
📈 PositiveBenzinga•Oct 31, 2025, 03:39 PM
BioCardia Announces University Of Wisconsin Enrolled First Patient In Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
📈 PositiveBenzinga•Oct 30, 2025, 12:04 PM
BioCardia Updates ATM Offering, Raising Maximum Aggregate Sale To $5,309,253
➖ NeutralBenzinga•Oct 24, 2025, 08:26 PM
BioCardia Regains Compliance With Nasdaq Listing Requirements
📈 PositiveBenzinga•Oct 2, 2025, 12:04 PM
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 04:19 PM
BioCardia Held Preliminary Clinical Consultation With Japan's Pharmaceutical and Medical Device Agency On Its CardiAMP Heart Failure Trial Results
➖ NeutralBenzinga•Sep 22, 2025, 12:14 PM
BioCardia shares are trading lower after the company announced the pricing of a $12 million public offering of 4.8 million shares and warrants at $1.25 per share and accompanying short-term warrant.
📉 NegativeBenzinga•Sep 18, 2025, 02:16 PM
BioCardia Prices Public Offering Of 4.8M Shares And Warrants At A Combined Price Of $1.25, For Up To $12M In Gross Proceeds
➖ NeutralBenzinga•Sep 18, 2025, 01:21 PM
BioCardia announces pricing of up to $12M public offering
➖ NeutralSeeking Alpha•Sep 18, 2025, 01:20 PM
BioCardia Announces Primary Endpoint Results Of Open Label Roll-In Cohort Of CardiAMP Cell Therapy In Chronic Myocardial Ischemia Trial
📈 PositiveBenzinga•Sep 18, 2025, 11:02 AM
Biocardia Inc Files For Offering Of Up To 2.8M Shares Of Common Stock Together With Up To 2.8M Common Warrants
📉 NegativeBenzinga•Sep 16, 2025, 01:49 PM
BioCardia Narrows Loss in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 11, 2025, 01:30 PM
BioCardia files prospectus for resale of 549K shares; stock down 8.6%
📉 NegativeSeeking Alpha•Jul 9, 2025, 09:34 PM
Frequently Asked Questions about BCDA
What is BCDA's current stock price?
BioCardia, Inc. (BCDA) is currently trading at $1.27 per share. The stock has moved -0.78% today.
What is the analyst price target for BCDA?
No analyst price targets are currently available for this stock.
What sector is BioCardia, Inc. in?
BioCardia, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BCDA's market cap?
BioCardia, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BCDA pay dividends?
No, BioCardia, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
ALZN
Alzamend Neuro, Inc.
$2.11
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
Explore stocks similar to BCDA for comparison